Publication | Open Access
EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth
25
Citations
29
References
2017
Year
EPCR represents a clinically relevant factor associated with poor outcome and a novel vulnerability to develop combination therapies for breast cancer patients.
| Year | Citations | |
|---|---|---|
2012 | 67.6K | |
2005 | 2.7K | |
2003 | 2.6K | |
2005 | 1.2K | |
2011 | 846 | |
2013 | 568 | |
1996 | 526 | |
2009 | 378 | |
2014 | 341 | |
2012 | 294 |
Page 1
Page 1